Antibiotic management of sepsis: current concepts

Background: The development of guidelines for sepsis management has improved disease survival and reduced treatment costs. Adequate antibiotic therapy is the cornerstone of sepsis treatment. Specific rules should be established in every institution according to its profiles. Objectives: To review the current knowledge about the best drugs to be used as empiric treatment for sepsis based on their clinical efficacy and costs. Methods: Medline 1950 – 2008 was searched using the following terms: sepsis, organ failure, system failure, SIRS, septic shock, antibiotic, pneumonia, urinary tract infection, urosepsis, catheter-related infection, bloodstream, abdominal infection, and surgical wound. Results/conclusion: For most septic shock patients, monotherapy is adequate and treatment should be initiated in the first hour after first sepsis-induced organ dysfunction. The drug of choice varies in different situations and choosing the right antibiotic enables better survival, fewer complications and shorter stays in intensive care.

[1]  J. Solomkin,et al.  Intra-abdominal infections. , 2009, The Surgical clinics of North America.

[2]  M. Levy,et al.  Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. , 2008, JAMA.

[3]  Nathan Shapiro,et al.  The costs and cost-effectiveness of an integrated sepsis treatment protocol , 2008, Critical care medicine.

[4]  J. Pugin,et al.  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. , 2008, American journal of respiratory and critical care medicine.

[5]  J. Marshall,et al.  The safety of targeted antibiotic therapy for ventilator-associated pneumonia: a multicenter observational study. , 2008, Journal of critical care.

[6]  D. Cook,et al.  Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia* , 2008, Critical care medicine.

[7]  M. Büchler,et al.  Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. , 2008, The Journal of antimicrobial chemotherapy.

[8]  Sean Keenan,et al.  Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. , 2008, Journal of critical care.

[9]  P. Tambyah,et al.  [European and Asian guidelines on management and prevention of catheter-associated urinary tract infections]. , 2008, Urologiia.

[10]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[11]  H. Evans,et al.  Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative gram-negative bacilli. , 2007, Surgical infections.

[12]  K. Naber,et al.  Optimal management of urosepsis from the urological perspective. , 2007, International journal of antimicrobial agents.

[13]  Derek C. Angus,et al.  National estimates of severe sepsis in United States emergency departments , 2007, Critical care medicine.

[14]  J. Rello,et al.  Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy* , 2007, Critical care medicine.

[15]  J. Sunderram,et al.  Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003* , 2007, Critical care medicine.

[16]  F. Gordo,et al.  Sepsis incidence and outcome: Contrasting the intensive care unit with the hospital ward* , 2007, Critical care medicine.

[17]  M. Kollef,et al.  Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?* , 2007, Critical care medicine.

[18]  D. Nicolau,et al.  Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. , 2007, Surgical infections.

[19]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. García de Lomas,et al.  The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. , 2007, Diagnostic microbiology and infectious disease.

[21]  M. Wolff,et al.  Early predictors for infection recurrence and death in patients with ventilator‐associated pneumonia , 2007, Critical care medicine.

[22]  Scott T. Micek,et al.  Before–after study of a standardized hospital order set for the management of septic shock* , 2006, Critical care medicine.

[23]  I. Raad,et al.  Optimal Antimicrobial Catheter Lock Solution, Using Different Combinations of Minocycline, EDTA, and 25-Percent Ethanol, Rapidly Eradicates Organisms Embedded in Biofilm , 2006, Antimicrobial Agents and Chemotherapy.

[24]  J. Jensen,et al.  Procalcitonin increase in early identification of critically ill patients at high risk of mortality* , 2006, Critical care medicine.

[25]  K. Naber,et al.  Incidence of nosocomial urinary tract infections on a surgical intensive care unit and implications for management. , 2006, International journal of antimicrobial agents.

[26]  M. Svendsen,et al.  Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. , 2006, International journal of antimicrobial agents.

[27]  F. Baquero,et al.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). , 2006, The Journal of antimicrobial chemotherapy.

[28]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[29]  Patrick Nicolas,et al.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis , 2006, Critical care medicine.

[30]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[31]  M. Bauer,et al.  Implementation of an evidence-based “standard operating procedure” and outcome in septic shock* , 2006, Critical care medicine.

[32]  C. Brun-Buisson,et al.  Validation of an algorithm based on direct examination of specimens in suspected ventilator-associated pneumonia , 2006, Intensive Care Medicine.

[33]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[34]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[35]  F. Gao,et al.  The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study , 2005, Critical care.

[36]  C. Viscoli,et al.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial , 2005, The Lancet.

[37]  M. M. van der Eerden,et al.  Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study , 2005, Thorax.

[38]  Matthew E Falagas,et al.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  D. Leaper,et al.  Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. , 2005, The Cochrane database of systematic reviews.

[40]  J. Fine,et al.  Meta-Analysis: Methods for Diagnosing Intravascular DeviceRelated Bloodstream Infection , 2005, Annals of Internal Medicine.

[41]  B. Goldstein,et al.  Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  M. Kollef,et al.  Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis , 2005, Critical care medicine.

[43]  J. Rello,et al.  Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[44]  ICU-Acquired Pneumonia Study Group,et al.  Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit , 1996, Intensive Care Medicine.

[45]  K. Olms,et al.  Ceftazidim mit und ohne Tobramycin versus Azlocillin plus Tobramycin in der Therapie bronchopulmonaler Infektionen bei Intensivpatienten , 1987, Infection.

[46]  K. Itani,et al.  Linezolid eradicates MRSA better than vancomycin from surgical-site infections. , 2004, American journal of surgery.

[47]  S. Opal,et al.  Sepsis associated with immunosuppressive medications: An evidence-based review , 2004, Critical care medicine.

[48]  F. Rodríguez de Castro,et al.  Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome , 2004, Thorax.

[49]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[50]  D. Snydman,et al.  Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. , 2004, American journal of respiratory and critical care medicine.

[51]  J. Handelsman,et al.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. , 2004, The Lancet. Infectious diseases.

[52]  H. Goossens,et al.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  F. Tubau,et al.  Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. , 2004, Archives of internal medicine.

[54]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[55]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[56]  A. Ma,et al.  Predicting bacteremia in patients with community-acquired pneumonia. , 2004, American journal of respiratory and critical care medicine.

[57]  Heinz Schneider,et al.  Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. , 2004, PharmacoEconomics.

[58]  L. Leibovici,et al.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. , 2004, BMJ.

[59]  F. Nepveu,et al.  Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. , 2004, Canadian respiratory journal.

[60]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[61]  R. Wunderink,et al.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. , 2003, Chest.

[62]  B. Kullberg,et al.  Voriconazole Salvage Treatment of Invasive Candidiasis , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[63]  E. P. Dellinger,et al.  Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  J. Rello,et al.  Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. , 2003, Chest.

[65]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[66]  Á. Soriano,et al.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  B. Boulanger,et al.  Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. , 2003, Clinical therapeutics.

[68]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[69]  Jordi Rello,et al.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. , 2002, Chest.

[70]  M. Niederman,et al.  Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. , 2002, Archives of internal medicine.

[71]  Marin H Kollef,et al.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.

[72]  T. Fabian,et al.  Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[74]  A. Nathens,et al.  The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. , 2002, Surgical infections.

[75]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[76]  R. Wunderink,et al.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. , 2001, Archives of internal medicine.

[77]  L. Saiman,et al.  Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[79]  L. Mermel,et al.  Guidelines for the Management of Intravascular Catheter-Related Infections , 2001, Infection Control & Hospital Epidemiology.

[80]  C. Ebener,et al.  Microbiology of postoperative peritonitis , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  A. Torres,et al.  Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin , 2000, Thorax.

[82]  I. Brook,et al.  Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. , 2000, Journal of medical microbiology.

[83]  S. Ewig,et al.  Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. , 2000, American journal of respiratory and critical care medicine.

[84]  A. Torres,et al.  Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. , 2000, American journal of respiratory and critical care medicine.

[85]  C. Verwaest.  Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[86]  T. Similowski,et al.  Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.

[87]  J. B. Price,et al.  Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. , 1999, Critical care medicine.

[88]  S. Wilson,et al.  Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. , 1999, The Journal of antimicrobial chemotherapy.

[89]  S. Ewig,et al.  Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies , 1999, Thorax.

[90]  M. Mufson,et al.  Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. , 1999, The American journal of medicine.

[91]  R. Gaynes,et al.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. , 1999, Critical care medicine.

[92]  J. Ramirez,et al.  Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. , 1999, The Journal of antimicrobial chemotherapy.

[93]  R. Salomão,et al.  Risk Factors for Death in Patients With Candidemia , 1998, Infection Control & Hospital Epidemiology.

[94]  R. Chioléro,et al.  Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis , 1998, Antimicrobial Agents and Chemotherapy.

[95]  G. Gottlieb,et al.  Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  M. Niederman,et al.  Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. , 1998, American journal of respiratory and critical care medicine.

[97]  R. Platt,et al.  Predicting Bacteremia in Patients with Sepsis Syndrome , 1997 .

[98]  D. Bates,et al.  Epidemiology of sepsis syndrome in 8 academic medical centers. , 1997, JAMA.

[99]  E. Taylor,et al.  A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. , 1997, The Journal of antimicrobial chemotherapy.

[100]  D. Bates,et al.  Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. , 1997, The Journal of infectious diseases.

[101]  K. Faulkner,et al.  Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. , 1996, The Journal of antimicrobial chemotherapy.

[102]  D. Snydman,et al.  Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. , 1995, Archives of internal medicine.

[103]  J. Bohnen,et al.  Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. , 1995, Surgery.

[104]  Jerome J. Schentag,et al.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group , 1994, Antimicrobial Agents and Chemotherapy.

[105]  A. Geddes,et al.  Efficacy of cefpirome in the treatment of septicaemia. , 1993, Scandinavian journal of infectious diseases. Supplementum.

[106]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[107]  M. Cheang,et al.  How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. , 1991, Annals of internal medicine.

[108]  L. Elting,et al.  Septicemia Due to Xanthomonas Species and Non‐Aeruginosa Pseudomonas Species: Increasing Incidence of Catheter‐Related Infections , 1990, Medicine.

[109]  M. Heimesaat,et al.  [Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients]. , 1987, Infection.

[110]  E. Dellinger,et al.  Implications of Leukocytosis and Fever at Conclusion of Antibiotic Therapy for Intra‐abdominal Sepsis , 1982, Annals of surgery.

[111]  R. Fairbrother.  Blood cultures. , 1949, The Practitioner.